These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37726842)

  • 1. Integrating synthetic accessibility with AI-based generative drug design.
    Parrot M; Tajmouati H; da Silva VBR; Atwood BR; Fourcade R; Gaston-Mathé Y; Do Huu N; Perron Q
    J Cheminform; 2023 Sep; 15(1):83. PubMed ID: 37726842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrosynthetic accessibility score (RAscore) - rapid machine learned synthesizability classification from AI driven retrosynthetic planning.
    Thakkar A; Chadimová V; Bjerrum EJ; Engkvist O; Reymond JL
    Chem Sci; 2021 Jan; 12(9):3339-3349. PubMed ID: 34164104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RetroGNN: Fast Estimation of Synthesizability for Virtual Screening and De Novo Design by Learning from Slow Retrosynthesis Software.
    Liu CH; Korablyov M; Jastrzębski S; Włodarczyk-Pruszyński P; Bengio Y; Segler M
    J Chem Inf Model; 2022 May; 62(10):2293-2300. PubMed ID: 35452226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FSM-DDTR: End-to-end feedback strategy for multi-objective De Novo drug design using transformers.
    Monteiro NRC; Pereira TO; Machado ACD; Oliveira JL; Abbasi M; Arrais JP
    Comput Biol Med; 2023 Sep; 164():107285. PubMed ID: 37557054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artificial Intelligence-Enabled De Novo Design of Novel Compounds that Are Synthesizable.
    Bhisetti G; Fang C
    Methods Mol Biol; 2022; 2390():409-419. PubMed ID: 34731479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reinvent 4: Modern AI-driven generative molecule design.
    Loeffler HH; He J; Tibo A; Janet JP; Voronov A; Mervin LH; Engkvist O
    J Cheminform; 2024 Feb; 16(1):20. PubMed ID: 38383444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical assessment of synthetic accessibility scores in computer-assisted synthesis planning.
    Skoraczyński G; Kitlas M; Miasojedow B; Gambin A
    J Cheminform; 2023 Jan; 15(1):6. PubMed ID: 36641473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MegaSyn: Integrating Generative Molecular Design, Automated Analog Designer, and Synthetic Viability Prediction.
    Urbina F; Lowden CT; Culberson JC; Ekins S
    ACS Omega; 2022 Jun; 7(22):18699-18713. PubMed ID: 35694522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is chemical synthetic accessibility computationally predictable for drug and lead-like molecules? A comparative assessment between medicinal and computational chemists.
    Bonnet P
    Eur J Med Chem; 2012 Aug; 54():679-89. PubMed ID: 22749644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target-specific novel molecules with their recipe: Incorporating synthesizability in the design process.
    Krishnan SR; Bung N; Srinivasan R; Roy A
    J Mol Graph Model; 2024 Jun; 129():108734. PubMed ID: 38442440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions.
    Ertl P; Schuffenhauer A
    J Cheminform; 2009 Jun; 1(1):8. PubMed ID: 20298526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RASA: a rapid retrosynthesis-based scoring method for the assessment of synthetic accessibility of drug-like molecules.
    Huang Q; Li LL; Yang SY
    J Chem Inf Model; 2011 Oct; 51(10):2768-77. PubMed ID: 21932860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AI-Driven Synthetic Route Design Incorporated with Retrosynthesis Knowledge.
    Ishida S; Terayama K; Kojima R; Takasu K; Okuno Y
    J Chem Inf Model; 2022 Mar; 62(6):1357-1367. PubMed ID: 35258953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating Reaction Schemes, Reagent Databases, and Virtual Libraries into Fragment-Based Design by Reinforcement Learning.
    Sauer S; Matter H; Hessler G; Grebner C
    J Chem Inf Model; 2023 Sep; 63(18):5709-5726. PubMed ID: 37668352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generative machine learning for de novo drug discovery: A systematic review.
    Martinelli DD
    Comput Biol Med; 2022 Jun; 145():105403. PubMed ID: 35339849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A flexible data-free framework for structure-based
    Du H; Jiang D; Zhang O; Wu Z; Gao J; Zhang X; Wang X; Deng Y; Kang Y; Li D; Pan P; Hsieh CY; Hou T
    Chem Sci; 2023 Nov; 14(43):12166-12181. PubMed ID: 37969589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AnoChem: Prediction of chemical structural abnormalities based on machine learning models.
    Gu C; Jang WD; Oh KS; Ryu JY
    Comput Struct Biotechnol J; 2024 Dec; 23():2116-2121. PubMed ID: 38808129
    [No Abstract]   [Full Text] [Related]  

  • 18. LOGICS: Learning optimal generative distribution for designing de novo chemical structures.
    Bae B; Bae H; Nam H
    J Cheminform; 2023 Sep; 15(1):77. PubMed ID: 37674239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine Learning in Computer-Aided Synthesis Planning.
    Coley CW; Green WH; Jensen KF
    Acc Chem Res; 2018 May; 51(5):1281-1289. PubMed ID: 29715002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DFRscore: Deep Learning-Based Scoring of Synthetic Complexity with Drug-Focused Retrosynthetic Analysis for High-Throughput Virtual Screening.
    Kim H; Lee K; Kim C; Lim J; Kim WY
    J Chem Inf Model; 2024 Apr; 64(7):2432-2444. PubMed ID: 37651152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.